0001387131-23-007603.txt : 20230616 0001387131-23-007603.hdr.sgml : 20230616 20230615182147 ACCESSION NUMBER: 0001387131-23-007603 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230524 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 231018854 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K/A 1 admp-8ka_052423.htm AMENDMENT TO FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

___________________________________________

CURRENT REPORT

___________________________________________

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 24, 2023

___________________________________________

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware		0-26372		82-0429727
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11682 El Camino Real, Suite 300

San Diego, CA

92130

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADMP		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Introductory Note

On May 26, 2023, Adamis Pharmaceuticals Corporation (the “Company” or “Adamis”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) reporting the completion of a merger transaction with DMK Pharmaceuticals Corporation (“DMK”), pursuant to the terms of an Agreement and Plan of Merger and Reorganization dated as of February 24, 2023 (the “Merger Agreement”), entered into by and among the Company, DMK and Aardvark Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Adamis. Pursuant to the Merger Agreement, DMK merged with and into Merger Sub (the “Merger”), with Merger Sub surviving the Merger and remaining a wholly owned subsidiary of the Company.

In accordance with and as permitted by Items 9.01(a) and 9.01(b) of Form 8-K, Adamis is filing this amendment to the Initial Form 8-K to provide certain historical and pro forma financial information that were not filed with the Initial Form 8-K, in reliance on the instructions to such Items.

Item 9.01.

Financial Statements and Exhibits.

(a)

Financial Statements of Business Acquired

The audited financial statements of DMK as of and for the years ended December 31, 2022 and 2021, and accompanying notes and the report of BF Borgers CPA PC, are filed as Exhibit 99.1 hereto and are incorporated herein by reference. The unaudited interim financial statements for the three months ended March 31, 2023 and 2022, are filed as Exhibit 99.2 hereto and are incorporated herein by reference.

(b)

Pro Forma Financial Information

The pro forma financial information required by Item 9.01(b) is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

(d)

Exhibits

23.1	Consent of BF Borgers CPA PC.
99.1	Audited Financial Statements of DMK Pharmaceuticals Corporation for the years ended December 31, 2022 and 2021.
99.2	Unaudited Financial Statements of DMK Pharmaceuticals Corporation for the three months ended March 31, 2023.
99.3	Unaudited Pro Forma Condensed Combined Consolidated Financial Information.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADAMIS PHARMACEUTICALS CORPORATION


Dated: June 15, 2023	By:	/s/ David C. Benedicto
	Name:	David C. Benedicto
	Title:	Chief Financial Officer

EX-23.1 2 ex23-1.htm CONSENT OF BF BORGERS CPA PC.

ADAMIS PHARMACEUTICALS CORPORATION 8-K/A

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the prospectuses included in the Registration Statements on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-194635, 333-201742, 333-211773, 333-218945, 333-226230, and 333-229379), and Form S-3 (Nos. 333-196976, 333-199454, 333-200447, 333-209401, 333-212880, 333-217400, 333-217408, 333-226100, 333-267365 and 333-249331) of Adamis Pharmaceuticals Corporation (the “Company”) of our report dated March 28, 2023 (which includes an explanatory paragraph relating to the uncertainty of the company’s ability to continue as a going concern), relating to the financial statements of DMK Pharmaceuticals Corporation for the years ended December 31, 2022 and 2021, which report is included in the Current Report on Form 8-K/A of the Company filed with the Securities and Exchange Commission.

/s/ BF BORGERS CPA PC

Lakewood, CO

June 12, 2023

EX-99.1 3 ex99-1.htm AUDITED FINANCIAL STATEMENTS OF DMK PHARMACEUTICALS

ADAMIS PHARMACEUTICALS CORPORATION 8-K/A

Exhibit 99.1

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of DMK Pharmaceuticals Corporation

Opinion on the Financial Statements

We have audited the accompanying balance sheets of DMK Pharmaceuticals Corporation as of December 31, 2022 and 2021, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

/S/ BF Borgers CPA PC

(PCAOB ID 5041)

We have served as the Company’s auditor since 2022

Lakewood, CO

March 28, 2023

DMK PHARMACEUTICALS CORPORATION

COMBINED BALANCE SHEETS

	December 31,
	2022			2021
Assets
Current assets:
Cash	$	131,310		$	2,804
Total current assets		131,310			2,804
Total assets	$	131,310		$	2,804

Liabilities and stockholders’ (deficit) equity
Current liabilities:
Accounts payable	$	5,560		$	—
Due to related party		4,621			285
Accrual Interest and other current liabilities		364,042			145,466
Deferred grant revenue		122,118			25,000
Total current liabilities		496,341			170,751

Long - Term Liabilities
Convertible debt - related party		3,093,224			2,228,373
Total liabilities	$	3,589,565		$	2,399,124
Commitments and contingencies (Note 5)
Stockholders’ (deficit) equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 38,837 and 15,288 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively		39			15
Additional paid-in capital		579,455			458,573
Accumulated deficit		(4,037,749	)		(2,854,908	)
Total stockholders’ (deficit)		(3,458,255	)		(2,396,320	)
Total liabilities, and stockholders’ (deficit) equity	$	131,310		$	2,804

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

COMBINED STATEMENTS OF OPERATIONS

	Twelve Months Ended December 31,
	2022			2021
Grant Revenue	$	100,350		$	168,593
Total revenue		100,350			168,593

Costs and expenses:
Research and development		336,554			430,260
General and administrative		727,527			1,734,971
Total operating expenses		1,064,081			2,165,231
Loss from operations		(963,731	)		(1,996,638	)
Other Income (Expense)
Interest expense		(219,110	)		(110,523	)
Net loss	$	(1,182,841	)	$	(2,107,161	)

Loss per common share - basic and diluted	$	(66.20	)	$	(137.83	)
Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted		17,869			15,288

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

COMBINED STATEMENTS OF CASH FLOWS

	Twelve Months Ended December 31,
	2022			2021
Operating activities
Net loss	$	(1,182,841	)	$	(2,107,161	)
Adjustments to reconcile net loss to net cash used in operating activities:
Convertible notes issued for services		873,033			1,877,144
Equity-based compensation		120,882			120,640
Changes in operating assets and liabilities:
Accounts payable		5,560			(30,010	)
Accrued expenses		218,600			110,813
Due to (from) related party		13,654			—
Deferred Revenue		97,118			25,000
Net cash provided by (used in) operating activities		146,006			(3,574	)
Financing activities
Payments on note payable		(17,500	)		—
Net cash (used in) financing activities		(17,500	)		—
Net increase in cash		128,506			(3,574	)
Cash at beginning of period		2,804			6,378
Cash at end of period	$	131,310		$	2,804

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

COMBINED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

										Total
					Additional					Stockholders’
	Common Stock				Paid-In		Accumulated			(Deficit)
	Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2020		15,288	$	15	$	337,933	$	(747,747	)	$	(409,799	)

Equity-based Compensation Expenses		—		—		120,640		—			120,640
Net loss		—		—		—		(2,107,161	)		(2,107,161	)
Balance at December 31, 2021		15,288	$	15	$	458,573	$	(2,854,908	)	$	(2,396,320	)


Equity-based Compensation Expenses		—		—		120,882		—			120,882
Shares issued for Merger		23,949		24		—		—			24
Common stock repurchased		400		—		—		—			—
Net loss		—		—		—		(1,182,841	)		(1,182,841	)
Balance at December 31, 2022		38,837	$	39		579,455		(4,037,749	)		(3,458,255	)

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND OPERATIONS

Nature of Business

DMK Pharmaceuticals Corporation. (“DMK” or the “Company”) is a pre-clinical stage biotechnology company focused on developing neurotherapies for central nervous system disorders of significant unmet need. The Company is located at 50 Division Street, Suite 501, Somerville, New Jersey.

Merger with Dina Pharma Inc.

On November 1, 2022, the Company entered into an Agreement and Plan of Merger (“Agreement”) with Dina Pharma Inc, a New Jersey corporation (“Dina”). Pursuant to the Agreement, Dina merged with and into DMK, with DMK as the surviving company (the “Dina Merger”). The Dina Merger was completed on November 28, 2022. Prior to the Dina Merger, Versi Group LLC (“Versi Group”) owned 100% of the outstanding shares of Dina and more than 90% of DMK. In exchange for the issuance of 23,949 shares of DMK common stock to Versi Group, the sole shareholder of Dina, DMK assumed all of the assets and liabilities of Dina, including two convertible promissory notes dated December 31, 2021 and October 1, 2022 issued by Dina to Ebrahim Versi, the Chief Executive Officer of DMK.

The transaction is considered a business combination under common control. A business combination involving entities under common control is a business combination in which all of the combining entities are ultimately controlled by the same party both before and after the business combination, and control is not transitory. Assets and liabilities for the combined entity were recorded at their same value as prior to the combination. The transaction combines two commonly controlled entities that historically have not been presented together and the resulting financial statement are effectively considered to be those of a different reporting entity, which requires retrospective combination of the entities for all periods presented as if the combination has been in effect since inception of common control in accordance with ASC 250-10-45-21.

Going Concern

DMK has no products approved for commercial sale, has not generated any revenue from product sales to date and has suffered recurring losses from operations since its inception. The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. DMK will require substantial additional capital to fund its research and development expenses related to its oncology drug. Based on DMK’s expected cash requirements, DMK believes that there is doubt that its existing cash and cash equivalents will be sufficient to fund its operations through one year from the financial statements’ issuance date. The Company intends to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments and may also consider new collaborations or selectively partnering its technology. However, the Company cannot provide any assurance that it will be successful in accomplishing any of its plans.

NOTE 2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying combined financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Reclassification

Certain reclassifications of prior period presentations have been made to conform to the current period presentation.

Cash and Cash Equivalents

DMK considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.

Intangibles

Intangible assets that have finite useful lives are amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. Intangible assets are included in other assets in the Company’s Combined Balance Sheets.

Financial Instruments and Credit Risks

Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.

Revenue Recognition

DMK’s source of revenue has been from research and developmental grants received from the United States National Institute of Health (“NIH”) and New Jersey state entities. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. The Company records revenue and a corresponding grants receivable when qualifying costs are incurred before the grants are received.

Research and Development Costs

Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.

Convertible Debt Instruments

The Company follows ASC 480-10, Distinguishing Liabilities from Equity in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of the issuer’s equity shares; or (c) variations inversely related to changes in the fair value of the issuer’s equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with remeasurements reported in change on fair value expense in the accompanying Statements of Operations. The convertible promissory notes issued by the Company is stock-settled debt in substance without beneficial conversion option since the conversion price was defined as the outstanding notes balance divided by certain percent of the market price of the common stock on the date of the conversion.

Equity-Based Compensation

DMK measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.

The Company uses the Black-Scholes option valuation model to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models include expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.

Income Taxes

Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2022 and 2021, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.

NOTE 3. CONVERTIBLE PROMISSORY NOTES TO RELATED PARTIES

During the year ended December 31, 2020, the Company issued an aggregated of $215,396 convertible promissory notes to related parties, The notes bear simple interest at 8% per annum, convertible to capital stock of the Company that are issued in a qualified financing event at 50% of the price per share or other unit of equity securities issued in such qualified financing. $198,600 of the notes were issued for consulting services in year 2020, $16,796 were issued for cash.

During the year ended December 31, 2021, the Company issued an aggregated of $1,864,864 convertible promissory notes to related parties including its Chief Executive Officer and Chief Operating Officer. The notes bear simple interest at 8% per annum, convertible to capital stock of the Company that are issued in a qualified financing event at 50% of the price per share or other unit of equity securities issued in such qualified financing. $1,863,600 of the notes were issued for consulting services in year 2021, $1,264 were issued for cash.

During the year ended December 31, 2022, the Company repaid $17,500 convertible notes to one of its debt holders, and issued $873,033 convertible notes to related parties including its Chief Executive Officer and Director of Research Operations. The convertible notes balance as of December 31, 2022 is $3,093,224.

NOTE 4. GRANT REVENUE

On April 21, 2021, NIH awarded a supplemental grant in the amount of $55,000 to the Company, these funds are restricted for the NIH I-Corps program and may not be used for any other purposes without approval.

On March 9, 2022, the Company received a grant of $25,000 from the New Jersey Small Business Innovation Research (“SBIR”) and Small Business Technology Transfer (“STTR”) Support Program. The Company recognized approximately $22,000 of the grant as grant revenue as of December 31, 2022.

On July 28, 2022, the Company entered into a Round 1 Catalyst Seed Research and Development Grant Program Agreement (“Grant Agreement”) with New Jersey Commission on Science, Innovation and Technology (“CSIT”). CSIT will provide the Company up to $150,000 to accelerate the development of technologies to transform new discoveries from the research stage into commercially viable products and services. This six year grant award expires on July 28, 2028. The Company may request in writing and without cost, a maximum of one three-month extension of the project term, subject to the written approval of CSIT. Subject to a written projection completion report delivered to CSIT within 30 days from the expiration date of July 28, 2023, 80% of the grant ($120,000) will be delivered within thirty days of the Grant Agreement is executed and all conditions set forth in Section 5 of the Grant Agreement are satisfied. The remaining 20% of the grant shall be issued within thirty days of receipt by CSIT of an approved project completion report. The Company received $120,000 from CSIT on August 18, 2022 and recorded deferred grant revenue as of December 31, 2022.

NOTE 5. COMMITMENTS AND CONTINGENCIES

License Agreement with Versi Group LLC

On August 18, 2016, the Company entered into a license agreement with Versi Group LLC, under which, the Company acquired an exclusive license to certain compounds and corresponding international patents used in the treatment of pain as an analgesic. In exchange for the license, the Company issued to Versi Group LLC 14,000 shares of the Company’s common stock.

On February 1, 2021, Dina entered into a license agreement with Versi Group LLC, under which, Dina acquired an exclusive license to certain compounds and corresponding international patents. The licensed compounds are the entire delta opioid receptor ligand library of compounds owned by Versi Group LLC and all data related to these compounds. In exchange for the license, Dina issued to Versi Group 20,000 shares of Dina’s common stock.

The cost incurred in obtaining the exclusive license to certain compounds and corresponding patents were expensed immediately since the assets have no alternative future use.

Lease Agreement

The Company presently leases office space under operating lease agreements on a month-to-month basis.

NOTE 6. FAIR VALUE OF FINANCIAL INSTRUMENTS

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:

Level 1-Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3-Significant unobservable inputs including DMK’ own assumptions in determining fair value.

The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and notes payable approximate their fair values due to the short-term nature of these instruments.

Stock based compensation expenses related to options issued under the 2016 Stock Plan (“Stock Plan”) were measured at Level 3 fair value for the years ended December 31, 2022 and 2021, respectively.

NOTE 7. STOCKHOLDERS’ EQUITY

Common Stock

In addition to the common stock issued to Versi Group LLC in exchange for the licenses disclosed in NOTE 5, the Company also has common shares issued to its consultants, employees and directors. As of December 31, 2022 and 2021 total common stock outstanding were 38,837 and 15,288, respectively.

NOTE 8. EQUITY-BASED COMPENSATION

The Company has granted options to employees and directors under the Stock Plan. The Stock Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, stock bonus and opportunities to make direct purchase of the Company’s common stock to employees and directors. The total number of shares of common stock reserved for the Stock Plan is 4,850.

During the twelve months ended December 31, 2022 and 2021, the Company awarded 900 stock options each year to its employees and directors, pursuant to the Stock Plan, with exercise price of $149. Stock options fully vest on the grant date and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the vesting period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants of $120,640 and $120,883 respectively, has been estimated with the following assumptions for the year ended December 31, 2022 and 2021:

	2022	2021
Risk-free interest rate	1.86%	0.75%
Volatility	132.64	133.26
Expected life (years)	6	6
Expected dividend yield	—	—

The following table summarizes stock option activity for employees and non-employees for the twelve months ended December 31, 2022 and 2021:

	Shares	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (in years)
Outstanding at December 31, 2020	2,700	$149	8.14
Granted	900	$149	10
Exercised	—
Forfeited	—
Expired	—
Outstanding at December 31, 2021	3,600	$149	7.64
Exercisable at December 31, 2021	3,600	$149	7.64

Granted	900	$149	10
Exercised	—
Forfeited	—
Expired	—
Outstanding at December 31, 2022	4,500	$149	7.14
Exercisable at December 31, 2022	4,500	$149	7.14

NOTE 9. INCOME TAX

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company recognized the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has a substantial net operating loss carryforward and the Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization.

Significant components of the Company’s net deferred tax assets for federal income taxes at December 31, 2021 and 2022 consist of the following:

	Years Ended December 31
	2022		2021
Net operating loss carryforward	$	584,260	$	524,507
Stock compensation		14,103		14,075
Deferred tax assets		598,363		538,582
Valuation allowance		-598,363		-538,582

Effective income tax asset	$	0	$	0
Effective tax rate		0%		0%

NOTE 10. SUBSEQUENT EVENTS

On February 27, 2023, Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, and DMK announced that the companies entered into an Agreement and Plan of Merger and Reorganization on February 24, 2023. Pursuant to the Agreement and Plan of Merger and Reorganization, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs.

EX-99.2 4 ex99-2.htm UNAUDITED FINANCIAL STATEMENTS OF DMK PHARMACEUTICALS

ADAMIS PHARMACEUTICALS CORPORATION 8-K/A

Exhibit 99.2

DMK PHARMACEUTICALS CORPORATION

COMBINED BALANCE SHEETS

	March 31, 2023			December 31, 2022

Assets
Current assets:
Cash	$	148,296		$	131,310
Total current assets		148,296			131,310
Total assets	$	148,296		$	131,310

Liabilities and stockholders' (deficit) equity
Current liabilities:
Accounts payable	$	4,871		$	5,560
Due to related party		6,041			4,621
Accrual Interest and other current liabilities		454,295			364,042
Deferred grant revenue		147,118			122,118
Total current liabilities		612,325			496,341

Long - Term Liabilities
Convertible debt - related party		3,093,224			3,093,224
Total liabilities	$	3,705,549		$	3,589,565
Commitments and contingencies (Note 5)
Stockholders' (deficit) equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 38,837 and 38,837 shares issued and outstanding at March 31, 2023 and December 31, 2012, respectively		39			39
Additional paid-in capital		579,455			579,455
Accumulated deficit		(4,136,747	)		(4,037,749	)
Total stockholders' (deficit)		(3,557,253	)		(3,458,255	)
Total liabilities, and stockholders' (deficit) equity	$	148,296		$	131,310

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

COMBINED STATEMENTS OF OPERATIONS

	Three Months Ended March 31,
	2023			2022
Grant Revenue	$	—		$	43,542
Total revenue		—			43,542

Costs and expenses:
Research and development		—			73,716
General and administrative		12,639			74,196
Total operating expenses		12,639			147,912
Loss from operations		(12,639	)		(104,370	)
Other Income (Expense)		1,265			73
Interest expense		(87,624	)		(42,402	)
Net loss	$	(98,998	)	$	(146,699	)

Loss per common share - basic and diluted	$	(2.55	)	$	(9.60	)
Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted		38,837			15,288

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

COMBINED STATEMENTS OF CASH FLOWS

	Three Months Ended March 31,
	2023			2022
Operating activities
Net loss	$	(98,998	)	$	(146,699	)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation		—			120,882
Changes in operating assets and liabilities:
Accounts payable		(689	)		—
Accrued expenses		90,253			42,276
Due to (from) related party		1,420			926
Deferred Revenue		25,000			—
Net cash provided by (used in) operating activities		16,986			17,385
Net increase in cash		16,986			17,385
Cash at beginning of period		131,310			2,804
Cash at end of period	$	148,296		$	20,189

See accompanying notes to combined financial statements.

DMK PHARMACEUTICALS CORPORATION

NOTES TO COMBINED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND OPERATIONS

Nature of Business

DMK Pharmaceuticals Corporation. (“DMK” or the “Companyis a pre-clinical stage biotechnology company focused on developing neurotherapies for central nervous system disorders of significant unmet need. The Company is located at 11 Sheephill Drive. Gladstone, New Jersey.

Business Combination under Common Control

On November 1, 2022, the Company entered into an Agreement and Plan of Merger (“Agreement”) with Dina Pharma Inc. a New Jersey corporation. Pursuant to the Agreement, DINA will merge with DMK (the “Merger”) accordance with the Agreement and the New Jersey Business Corporation Act. Upon consummation of the Merger, the DINA will cease to exist, and DMK will continue as the surviving company. The merger was completed on November 28, 2022. Prior to the merger, the Versi Group LLC owned 100% of the outstanding shares of Dina Pharmaceuticals, Inc., and more than 90% of DMK Pharmaceuticals, Corporation. The transaction is considered a business combination under common control. A business combination involving entities under common control is a business combination in which, all the combing entities are ultimately controlled by the same party both before and after the business combination and control is not transitory. Assets and liabilities for the combined entity were recorded at their same value as prior to the combination. The transaction combines two commonly controlled entities that historically have not been presented together, the resulting financial statement are effectively considered to be those of a different reporting entity, which requires retrospective combination of the entities for all periods presented as if the combination has been in effect since inception of common control in accordance with ASC 250-10-45-21.

Merger Agreement

One February 24, 2023, Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, and DMK Pharmaceuticals, Corporation announced that the companies have entered into an Agreement and Plan of Merger and Reorganization. Pursuant to the Agreement and Plan of Merger and Reorganization, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs.

Going Concern

DMK has no products approved for commercial sale, has not generated any revenue from product sales to date and has suffered recurring losses from operations since its inception. The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. DMK will require substantial additional capital to fund its research and development expenses related to its oncology drug. Based on DMK’ expected cash requirements, DMK believes that there is doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements issuance date. The Company intends to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments and may also consider new collaborations or selectively partnering its technology. However, the Company cannot provide any assurance that it will be successful in accomplishing any of its plans.

NOTE 2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying combined financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").

Use of Estimates

Cash and Cash Equivalents

DMK considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.

Intangibles

Financial Instruments and Credit Risks

Revenue Recognition

DMK’ source of revenue has been from a grant received from the National Institute of Health. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. The Company records revenue and a corresponding grants receivable when qualifying costs are incurred before the grants are received.

Research and Development Costs

Convertible Debt Instruments

Equity-Based Compensation

Income Taxes

Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2022 and 2021, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.

NOTE 3. CONVERTIBLE PROMISSORY NOTES TO RELATED PARTIES

During the year ended December 31, 2020, the Company issued an aggregated of $215,396 convertible promissory notes to relates parties, The notes bear simple interest at 8% per annum, convertible to capital stock of the Company that are issued in a qualified financing event at 50% of the price per share or other unit of equity securities issued in such qualified financing. $198,600 of the notes were issued for consulting services in year 2020, $16,796 were issued for cash.

During the year ended December 31, 2021, the Company issued an aggregated of $1,864,864 convertible promissory notes to related parties including its Chief Executive Officer and Director of Research Operations, The notes bear simple interest at 8% per annum, convertible to capital stock of the Company that are issued in a qualified financing event at 50% of the price per share or other unit of equity securities issued in such qualified financing. $1,863,600 of the notes were issued for consulting services in year 2021, $1,264 were issued for cash.

During the year ended December 31, 2022, the Company repaid $17,500 convertible notes to one of its debt holders, and issued $873,033 convertible notes to related parties including its Chief Executive Officer and Director of Research Operations. Convertible notes balance as of December 21, 2022 is $3,093,224.

During the three months ended March 31, 2023, there was no convertible notes issued to by the Company.

NOTE 4. DEFERRED GRANT REVENUE and GRANT REVENUE

On March 9, 2022, the Company received a grant of $25,000 from New Jersey Small Business Innovation Research (“SBIR”) and Small Business Technology Transfer (“STTR”) Support Program. The Company recognized approximately $22,000 of the grant as grant revenue as of December 31, 2022.

On July 28, 2022, the Company entered into a Round 1 Catalyst Seed Research and Development Grant Program Agreement (‘Grant Agreement”) with New Jersey Commission on Science, Innovation and Technology (“CSIT”). CSIT will provide the Company up to $150,000 to accelerate the development of technologies to transform new discoveries from research state into commercially viable products and services. This six – year grant award expires on July 28, 2028. The Company may request in writing and without cost a maximum one three-month extension of the project term, subject to the written approval of CSIT. Subject to a written projection completion report delivered to CSIT within in 30 days from the expiration date of July 28, 2023, 80% of the grant ($120,000) is delivered within thirty days of the Grant Agreement is executed and all conditions set forth in Section 5 of the Grant Agreement. The remaining 20% of the grant shall be issued within thirty days of receipt by the CSIT of an approved project completion report. The Company received $120,000 from CSIT on August 18, 2022 and recorded deferred grant revenue as of December 31, 2022.

On February 8, 2023, The Company entered into Small Business Innovation Research and Small Business Technology Transfer Program Grant Agreement with New Jersey Commission on Science, Innovation and Technology(“CSIT”), under which CSIT will provide grants up to $25,000 to the Company to enhance the innovative economy in New Jersey. The Company received the $25,000 grant in March 2023, and reported as deferred grant revenue as of March 31, 2023.

Deferred revenue balance is $147,118 and 122,118 as of March 31, 2023 and December 31, 2022, respectively.

Grant revenue amount is $0 and $43,452 for the three months ended March 31, 2022 and 2023, respectively. Grant revenue recognized during the three months ended March 31, 2022 was related to qualified expense incurred for Developing a Novel Mixed Opioid Agonist for the Treatment of Opioid Use Disorder project sponsored by National Institute on Drug Abuse.

NOTE 5. COMMITMENTS AND CONTINGENCIES

License Agreement with the Versi Group LLC

On August 18^th, 2016, the Company entered into a license agreement with Versi Group LLC, under which, the Company acquired an exclusive license to certain compound and corresponding international patents used in the treatment of pain as an analgesic. In exchange for the license, the Company issued to Versi Group LLC 14,000 shares of the Company’s common stock.

On February 1^st, 2021, Dina entered into a license agreement with Versi Group LLC, under which, Dina acquired an exclusive license to certain compounds and corresponding international patents. The licensed compounds are the entire delta opioid receptor ligand library of compounds owned by the Versi Group LLC and all data related to these compounds. In exchange for the license, Dina issued to Versi Group 20,000 shares of Dina’s common stock.

The cost incurred in obtaining the exclusive license to certain compound and corresponding patents were expensed immediately since the assets have no alternative future use.

Lease Agreement

The Company presently leases office space under operating lease agreements on a month to month basis.

NOTE 6. FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1-Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 3-Significant unobservable inputs including DMK’ own assumptions in determining fair value.

The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.

Stock based compensation expenses related to options issued under the 2016 Stock Plan (“Stock Plan”) were measured at Level 3 fair value for the three months ended March 31, 2022.

NOTE 7. STOCKHOLDERS' EQUITY

Common Stock

In November 2022, DMK acquired DINA and issued 23,949 DMK shares to Versi Group LLC, single shareholder of DINA. The transaction is treated as business combination under common control. See disclosure in NOTE1.

In addition to the common stock issued to Versi Group LLC in exchange for the licenses disclosed in NOTE 5, the Company also has common shares issued to its consultants, employees and director. As of December 31, 2022 and 2021 total common stock outstanding were 38,837 and 15,288, respectively.

NOTE 8. EQUITY-BASED COMPENSATION

The Company has granted options to employees and director under the 2016 Stock Plan (“Stock Plan”). The Stock Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, stock bonus and opportunities to make direct purchase of the Company’s common stock to employees and director. Total common stock reserved for the Stock Plan is 4,850.

During the three months ended March 31, 2022, the Company awarded 900 stock options to its employees and director, pursuant to the plan described above, with exercise price of $149. Stock options fully vest on the grant date and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the vesting period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants was $120,882 , has been estimated with the following assumptions for the three months ended March 31, 2022. There were no stock option granted by the Company for the three months ended March 31, 2023.

	2022
Risk-free interest rate	1.86%
Volatility	132.64
Expected life (years)	6
Expected dividend yield	-

The following table summarizes stock option activity for employees and non-employees for the three months ended March 31, 2023 and 2022:

	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)
Outstanding at December 31, 2021		3,600	$	149		7.64
Granted		900	$	149		10
Exercised		—
Forfeited		—
Expired		—
Outstanding at March 31, 2022		4,500	$	149		7.90
Exercisable at March 31, 2022		4,500	$	149		7.90

Granted		—
Exercised		—
Forfeited		—
Expired		—
Outstanding at Mach 31, 2023		4,500	$	149		6.90
Exercisable at March 31, 2023		4,500	$	149		6.90

NOTE 10. SUBSEQUENT EVENTS

The Company’s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.

EX-99.3 5 ex99-3.htm UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL INFORMATION

ADAMIS PHARMACEUTICALS CORPORATION 8-K/A

Exhibit 99.3

Unaudited Pro Forma Condensed Combined Consolidated Financial Information

Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) has determined the merger transaction with DMK Pharmaceuticals Corporation (“DMK”) meets the definition of an acquisition of a business as defined in Rule 11-01(d) of Regulation S-X of the Securities Exchange Commission (“SEC”). The accompanying unaudited Pro Forma Condensed Combined Consolidated Balance Sheet as of March 31, 2023 and Statements of Operations of the Company and DMK Pharmaceuticals Corporation for the three months ended March 31, 2023 and year ended December 31, 2022 were prepared for the purpose of complying with Rule 8-04 of Regulation S-X of the SEC and for inclusion in the Company’s filings with the SEC. The following unaudited pro forma condensed combined consolidated financial information presented has been prepared in accordance with Article 11 of Regulation S-X, Pro Forma Financial Information, as amended by the final rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses”, and is being provided pursuant to Rule 8-04 of Regulation S-X. Release No. 33-10786 replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction (“Transaction Accounting Adjustments”) and the option to present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (“Management’s Adjustments”). The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies.

The Company has accounted for the merger transaction with DMK as of May 25, 2023, as an asset acquisition, in accordance with FASB Accounting Standards Codification (“ASC”) Topic 805 “Business Combinations” (“ASC 805”). The Company determined the merger constituted an acquisition of assets as substantially all of the fair value of the gross assets acquired were concentrated in a single identifiable asset (DP1-125), and therefore, the acquisition is not considered a business. With an asset acquisition, acquired in-process research and development (“acquired IPR&D”) is expensed at acquisition date, unless it has an alternative future use. Additionally, in an asset acquisition, direct transaction costs are accumulated, a component of the consideration transferred and expensed with the acquired IPR&D that has no alternative use. For accounting purposes, the Company is considered to be acquiring DMK in the merger.

The unaudited pro forma condensed combined consolidated statement of operations as of March 31, 2023, and December 31, 2022, do not include any adjustments for income taxes relating to the merger as the tax impact is still being evaluated. The pro forma financial information is presented for illustrative purposes only, does not purport to present Adamis’ financial position or the results of operations had the merger transaction actually been completed as of the date indicated, and does not project the Company’s financial position or results of operations for any future date or period. Further, are based on assumptions that Adamis believes are reasonable under the circumstances and is intended for informational purposes only.

The unaudited pro forma condensed combined consolidated financial statements are intended to show how the merger might have affected the historical financial statements if the merger had been contemplated on January 1, 2022, for the purposes of the statement of operations, and as of March 31, 2023, for the purposes of the balance sheet.

The unaudited pro forma condensed combined consolidated statement of operations presented below are based on the historical financial statements of Adamis and DMK, adjusted to give effect to the acquisition of DMK by Adamis for accounting purposes. The pro forma adjustments are described in the accompanying notes presented on the following pages.

The unaudited pro forma condensed combined consolidated statement of operations has been derived from and should be read in conjunction with the historical consolidated financial statements and related notes of Adamis and DMK which are included, with respect to DMK, filed in this Form 8-K, and with respect to Adamis, in Adamis’ annual report on Form 10-K for the year ended December 31, 2022 and Adamis’ quarterly report on Form 10-Q for the period ended March 31, 2023.

UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED BALANCE SHEETS

As of March 31, 2023


	Historical
	Adamis March 31,			DMK March 31,			Transaction Accounting				Pro Forma
ASSETS	2023			2023			Adjustments				Combined
CURRENT ASSETS
Cash	$	3,099,843		$	148,296		$	—			$	3,248,139
Restricted Cash		30,079			—			—				30,079
Receivable from Fagron		21,173			—			—				21,173
Inventories		664,358			—			—				664,358
Prepaid Expenses and Other Current Assets		750,272			—			—				750,272
Current Assets of Discontinued Operations		2,981,305			—			—				2,981,305
		7,547,030			148,296			—				7,695,326
LONG TERM ASSETS
Property, Plant & Equipment, net		1,244,669			—			—				1,244,669
Right-of-Use Assets		232,222			—			—				232,222
Other Non-Current Assets		52,174			—			—				52,174

Total Assets	$	9,076,095		$	148,296		$	—			$	9,224,391
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts Payable	$	9,780,979		$	4,871		$	—			$	9,785,850
Due to Related Party					6,041			—				6,041
Accrued Other Expenses		1,829,554			454,295			(450,889	)	B		2,983,082
								657,666		F		—
								492,456		K		—
Product Recall Liability		130,152			—			—				130,152
Lease Liabilities, current portion		250,361			—			—				250,361
Deferred Revenue, current portion		27,779			147,118			—				174,897
Current Liabilities of Discontinued Operations		929,700			—			—				929,700
		12,948,525			612,325			699,233				14,260,083

LONG-TERM LIABILITIES
Deferred Revenue, net of current portion		171,302			—			—				171,302
Convertible Debt - Related Party		—			3,093,224			(3,093,224	)	B		—
Warrant Liabilities, at fair value		5,480,646			—			—				5,480,646

Total Liabilities		18,600,473			3,705,549			(2,393,991	)			19,912,031

COMMITMENTS AND CONTINGENCIES

MEZZANINE EQUITY
Convertible Preferred Stock		157,303			—			—				157,303

STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred Stock		—			—			—				—
Common Stock		15,051			39			(39	)	C(1)		15,330
								279		C		—
Additional Paid-in Capital		303,815,511			579,455			(579,455	)	H		309,841,079
								415,809		I		—
								5,609,759		C		—
Accumulated Deficit		(313,506,993	)		(4,136,747	)		4,136,747		A		(320,696,102	)
								(7,189,109	)	D		—
Treasury Stock		(5,250	)		—			—				(5,250	)
Total Stockholders’ Deficit		(9,681,681	)		(3,557,253	)		2,393,991				(10,844,943	)
Total Liabilities, Mezzanine Equity and Stockholders’ Deficit	$	9,076,095		$	148,296		$	—			$	9,224,391

See accompanying notes.

UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED STATEMENT OF OPERATIONS

Three Months Ended March 31, 2023

	Historical
	Adamis Three Months Ended March 31, 2023			DMK Three Months Ended March 31, 2023			Transaction Accounting Adjustments			Pro Forma Combined
REVENUE, net	$	1,453,000		$	—		$	—		$	1,453,000
COST OF GOODS SOLD		1,788,066			—			—			1,788,066
Gross Loss		(335,066	)		—			—			(335,066	)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		4,782,086			12,639			100,000	J		4,894,725
RESEARCH AND DEVELOPMENT		1,310,529			—			32,500	J		1,343,029
Total Operating Expenses		(6,092,615	)		(12,639	)		(132,500	)		(6,237,754	)

Loss from Operations		(6,427,681	)		(12,639	)		132,500			(6,572,820	)

OTHER EXPENSE
Interest Income		11			—			—			11
Interest Expense and Other Income (Expense)		(113,034	)		(86,359	)		86,359	G		(113,034	)
Excess of March 2023 Warrant Fair Value over Offering Proceeds		(2,476,109	)		—			—			(2,476,109	)
Change in Fair Value of Warrant liability		2,205			—			—			2,205
Total Other Expense		(2,586,927	)		(86,359	)		86,359			(2,586,927	)

Net Loss from Continuing Operations before income taxes	$	(9,014,608	)	$	(98,998	)	$	(46,141	)	$	(9,159,747	)
Income Tax Expense		—			—			—			—
Net Loss from Continuing Operations	$	(9,014,608	)	$	(98,998	)	$	(46,141	)	$	(9,159,747	)
DISCONTINUED OPERATIONS
Net Income from Discontinued Operations before income Taxes	$	71,701		$	—		$	—		$	71,701
Income Taxes - Discontinued Operations		—			—			—			—
Net Income from Discontinued Operations	$	71,701		$	—		$	—		$	71,701
Net Loss Applicable to Common Stock	$	(8,942,907	)	$	(98,998	)	$	(46,141	)	$	(9,088,046	)

Basic and Diluted Loss Per Share:

Continuing Operations	$	(0.06	)	$	(2.55	)				$	(3.68	)
Discontinued Operations	$	—		$	—					$	(0.03	)
Basic and Diluted Net Loss Per Share	$	(0.06	)	$	(2.55	)				$	(3.65	)

Basic and Diluted Weighted Average Shares Outstanding		152,916,598			38,837						2,487,338

See accompanying notes.

UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED STATEMENT OF OPERATIONS
For the Year Ended December 31, 2022

	Historical
	Adamis Year Ended December 31, 2022			DMK Year Ended December 31, 2022			Transaction Accounting Adjustments			Pro Forma Combined
REVENUE, net	$	4,756,078		$	100,350		$	—		$	4,856,428
COST OF GOODS SOLD		6,187,486			—						6,187,486
Gross Loss		(1,431,408	)		100,350			—			(1,331,058	)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		13,247,594			727,527			400,000	J		14,375,121
Acquired IPR&D		—			—			7,938,202	E		7,938,202
RESEARCH AND DEVELOPMENT		10,379,964			336,554			130,000	J		10,846,518
Total Operating Expenses		(23,627,558	)		(1,064,081	)		(8,468,202	)		(33,159,841	)
Loss from Operations		(25,058,966	)		(963,731	)		(8,468,202	)		(34,490,899	)

OTHER EXPENSE
Interest Income		44,126			—			—			44,126
Interest Expense and Other Income (Expense)		—			(219,110	)		219,110	G		—
PPP2 Loan Contingent loss		(1,787,417	)		—			—			(1,787,417	)
Loss on Fagron Variable Consideration, net		(962,619	)		—			—			(962,619	)
Insurance Proceeds		600,000			—			—			600,000
Gain on ERC		875,307			—			—			875,307
Change in Fair Value of Warrant liability		92,163			—			—			92,163
Total Other Expense		(1,138,440	)		(219,110	)		219,110			(1,138,440	)
Net Loss from Continuing Operations before income taxes	$	(26,197,406	)	$	(1,182,841	)	$	(8,249,092	)	$	(35,629,339	)
Income Tax Expense		(2,000	)		—						(2,000	)
Net Loss from Continuing Operations	$	(26,199,406	)	$	(1,182,841	)	$	(8,249,092	)	$	(35,631,339	)
DISCONTINUED OPERATIONS
Net Loss from Discontinued Operations before income Taxes	$	(278,867	)	$	—		$	—		$	(278,867	)
Income Taxes - Discontinued Operations		—			—			—			—
Net Loss from Discontinued Operations	$	(278,867	)	$	—		$	—		$	(278,867	)
Net Loss Applicable to Common Stock	$	(26,478,273	)	$	(1,182,841	)	$	(8,249,092	)	$	(35,910,206	)

Basic and Diluted Loss Per Share:

Continuing Operations	$	(0.17	)	$	(66.20	)				$	(14.58	)
Discontinued Operations	$	—		$	—					$	(0.11	)
Basic and Diluted Net Loss Per Share	$	(0.18	)	$	(66.20	)				$	(14.70	)

Basic and Diluted Weighted Average Shares Outstanding		149,851,278			17,869						2,433,548

See accompanying notes.

Notes to the Unaudited Pro Forma Condensed Combined Consolidated Financial Statements

1.	Basis of Presentation

On May 25, 2023, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”), a Delaware corporation, completed its merger transaction with DMK Pharmaceuticals Corporation (“DMK”), a privately held, clinical stage neuro-biotechnology company focused on developing novel therapies for opioid use disorder and other neuro-based conditions, in accordance with the terms of an Agreement and Plan of Merger and Reorganization dated as of February 24, 2023 (the “Merger Agreement”), entered into by and among the Company, DMK and Aardvark Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Adamis (“Merger Sub”). Effective May 25, 2023, pursuant to the Merger Agreement, DMK merged with and into Merger Sub (the “Merger”), with Merger Sub surviving the Merger and remaining a wholly owned subsidiary of the Company. In connection with the Merger, the name of Merger Sub as the surviving corporation was changed to DMK Pharmaceuticals Corporation.

As a result of the consummation of the Merger, and after giving effect to the 70-for-1 reverse stock split of the outstanding shares of common stock of Adamis, effective at the effective time of the Merger (the “Effective Time”), the shares of DMK common stock then outstanding were canceled and automatically converted into and became the right to receive 302,815 shares of Adamis common stock and, with respect to certain former DMK stockholders, 1,941.2 shares of Series E Convertible Preferred Stock (“Series E Preferred”) of the Company. The issuance of the shares of Adamis common stock and Series E Preferred to the former stockholders of DMK in connection with the Merger was approved by the Company’s stockholders at a special meeting of stockholders held on May 15, 2023.

At the Effective Time, outstanding DMK stock options to purchase shares of DMK common stock were assumed by the Company and became options to purchase a total of 231,490 shares of Adamis common stock, with proportionate adjustments to the exercise prices per share of such options based on the exchange ratio determined pursuant to the Merger Agreement. The assumed options continue to be governed by the terms of the DMK 2016 Stock Plan, which was assumed by the Company in connection with the closing of the Merger. The replacement value of the options assumed was treated as additional purchase price consideration paid by Adamis.

The unaudited pro forma condensed combined consolidated statement of operations for the three months ended March 31, 2023, and the year ended December 31, 2022, combine the audited historical statements of operations of Adamis and DMK for their respective year ended December 31, 2022, and give pro forma effect to the Merger as if it had been completed on January 1, 2022.

The unaudited pro forma combined financial statements reflect the issuance of 302,815 shares of Adamis common stock and 1,941.2 Series E Preferred Shares (“Series E”) convertible into shares of Adamis common stock at a conversion rate of 1,000 common shares for 1 Series E Preferred Share (subject to beneficial ownership limitations of 9.99%) to former DMK shareholders. Based on the limited exception under ASC 480-10-S99-3A(3)(f) for equity instruments that are subject to a deemed liquidation provision “if all of the holders of equally and more subordinated equity instruments of the entity would always be entitled to also receive the same form of consideration (for example, cash or shares) upon the occurrence of the event that gives rise to the redemption (that is, all subordinate classes would also be entitled to redeem), the Company determined that the Series E should be classified as permanent equity. Additionally, based on the accounting guidance per ASC 260-10-45-40 as the Series E receive no preferred dividends, there is no adjustment to the numerator for the calculation of diluted EPS and under the guidance of ASC 260-10-45-4, the Series E common stock equivalents are not included in the calculation of diluted EPS as this would be anti-dilutive (since the Company generates net losses).

2.	Purchase Price

The total purchase price of the Merger is as follows:

Fair Value of Adamis Common Stock issued to DMK shareholders	$	757,038
Fair Value of Adamis Series E Preferred Stock issued to DMK shareholders		4,853,000
Fair value of DMK options assumed and replaced by Adamis		415,809
Adamis Transaction Costs		1,406,759
DMK incurred Merger-related costs paid for by Adamis		492,456
Total Consideration Transferred	$	7,925,062

For pro forma purposes, in determining the number of Adamis shares of common stock issued as part of the purchase price, the number of shares of DMK common stock outstanding was 43,621. Additionally, the beneficial ownership limitations as set forth in the Merger Agreement were applied to determine the amount common stock and preferred stock issuable. The fair value of the common stock issued was based on the closing stock price of Adamis on the closing date, May 25, 2023. For pro forma purposes, the fair value of the DMK options assumed and replaced were based on the Black Scholes option pricing model, taking into consideration the implied fair value per share value of the DMK common stock and DMK volatility based on the DMK peer group stock price analysis. Additionally, costs incurred by DMK related to the Merger and paid by Adamis and the asset acquisition transaction costs were primarily based on actual invoices.

The allocation of the total purchase price is estimated as follows:

Assets Acquired:
Cash	$	148,296
Total assets acquired		148,296
Liabilities Assumed:
Accounts Payable		4,871
Due to Related Party		6,041
Accrued Expenses		3,406
Deferred Grant Revenue		147,118
Total liabilities assumed		161,436
Net Liabilities acquired		(13,140	)
Acquired In-Process R&D (IPR&D)		7,938,202
Total Purchase Price	$	7,925,062

The Company determined due to the early stage of development related to the acquired IPR&D that there was no alternative use, and, as such the acquired IPR&D was expensed. Direct asset acquisition transaction costs were accumulated, a component of the consideration transferred and expensed with the acquired IPR&D.

3.	Transaction adjustments to Unaudited Pro Forma Condensed Combined Financial Statements

Adjustments included in the column under the heading “Transaction Accounting Adjustments” are primarily based on information contained within the Merger Agreement.

A: To reflect the elimination of DMK’s historical accumulated deficit.

B: To reflect the settlement of DMK’s convertible notes and associated accrued interest prior to the closing of the Merger as these were not assumed by Adamis.

C: To reflect the consideration transferred of 302,815 shares of Adamis common stock and 1,941,200 shares of Series E convertible preferred stock for all outstanding shares of DMK common stock.

C1: To reflect the elimination of DMK historical common stock.

D: Represents the adjustment to accumulated deficit related to expensing acquired IPR&D.

Accumulated Deficit transaction adjustment reconciliation to total acquired IPR&D:

Acquired IPR&D per third-party valuation	$	6,531,443
Total Adamis transaction costs		1,406,759
Total Acquired IPR&D		7,938,202
Less: Transaction costs accrued as of March 31, 2023, reflected in Adamis historical statement of operations		(749,093	)
Accumulated Deficit transaction adjustment	$	7,189,109

E: Represents the allocation of the purchase price (inclusive of Adamis transaction costs) to acquired IPR&D. As the Merger was determined to be an asset acquisition and the acquired IPR&D was determined to have no alternative future use, the acquired IPR&D was expensed. See Note 2 for the total purchase price.

F: To accrue for Adamis transaction costs not yet reflected in Adamis’ balance sheet as of March 31, 2023.

G: To remove interest expense related to the convertible notes as these were not assumed by Adamis and are reflected in stockholders’ deficit.

H: To reflect the elimination of historical DMK additional paid-in capital.

I: To reflect the fair value of DMK options assumed and replaced by Adamis as part of the purchase consideration of the Merger.

J: To reflect the incremental salary expense for the combined company related to Adamis hiring two former DMK employees in connection with the Merger. The additional salary expense relates to cash compensation only, is recurring and may increase.

Included in selling, general and administrative expense is the incremental salary expense related to the Adamis CEO position that was assumed by DMK’s former CEO. The incremental difference in salary is estimated at $400,000 per year.

Included in research and development expense is the salary expense related to the new Adamis R&D position assumed by a DMK R&D employee. The incremental difference in salary is estimated at $130,000 per year.

K: To reflect Adamis additional purchase consideration related to DMK incurred Merger costs.

4.	Computation of Pro Forma Combined Net Loss Per Common Share

The unaudited pro forma weighted average number of basic and diluted shares outstanding and pro forma net loss per common share basic and diluted are calculated as follows:

	Three Months Ended March 31, 2023			Year Ended December 31, 2022
Adamis weighted average shares outstanding - basic and diluted (recast, see below)		2,184,523			2,140,733
Adamis common stock issued to DMK shareholders pursuant to the Merger Agreement (See Note 1)		302,815			302,815
Pro forma weighted average shares outstanding – basic and diluted		2,487,338			2,443,548
Pro forma net loss attributable to common shareholders – basic	$	(9,088,046	)	$	(35,910,206	)
Pro forma net loss attributable to common shareholders – diluted	$	(9,088,046	)	$	(35,910,206	)
Pro forma net loss per common share – basic	$	(3.65	)	$	(14.70	)
Pro forma net loss per common share – diluted	$	(3.65	)	$	(14.70	)

To reflect the 1 for 70 reverse stock split approved by Adamis’ Board of Directors in May 2023, the basic and diluted average shares outstanding have been recast. Additionally, the basic and diluted net loss per share (continuing operations) have been revised using the recast basic and diluted weighted average shares outstanding.

As Reported:
	Three Months Ended
	March 31, 2023
Continuing Operations	$	(0.06	)
Basic and Diluted Net Loss Per Share	$	(0.06	)

Basic and Diluted Weighted Average Shares Outstanding		152,916,598

As Adjusted for the 1:70 Reverse Stock Split (unaudited):
	Three Months Ended
	March 31, 2023
Continuing Operations	$	(4.13	)
Basic and Diluted Net Loss Per Share	$	(4.09	)

As reported Basic and Diluted Weighted Average Shares Outstanding		152,916,598
Divided by 1 for 70 reverse stock split		70
Basic and Diluted Weighted Average Shares Outstanding		2,184,523

As Reported:
	Year Ended
	December 31, 2022
Continuing Operations	$	(0.17	)
Basic and Diluted Net Loss Per Share	$	(0.18	)

Basic and Diluted Weighted Average Shares Outstanding		149,851,278

As Adjusted for the 1:70 Reverse Stock Split (unaudited):
	Year Ended
	December 31, 2022
Continuing Operations	$	(12.24	)
Basic and Diluted Net Loss Per Share	$	(12.37	)

As reported Basic and Diluted Weighted Average Shares Outstanding		149,851,278
Divided by 1 for 70 reverse stock split		70
Basic and Diluted Weighted Average Shares Outstanding		2,140,733

EX-101.SCH 6 admp-20230525.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 admp-20230525_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 admp-20230525_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	May 25, 2023
Cover [Abstract]
Document Type	8-K/A
Amendment Flag	true
Amendment Description	Amendment No, 1
Document Period End Date	May 24, 2023
Entity File Number	0-26372
Entity Registrant Name	ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key	0000887247
Entity Tax Identification Number	82-0429727
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11682 El Camino Real
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	(858)
Local Phone Number	997-2400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	ADMP
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 10 admp-8ka_052423_htm.xml IDEA: XBRL DOCUMENT 0000887247 2023-05-25 2023-05-25 iso4217:USD shares iso4217:USD shares 0000887247 true Amendment No, 1 8-K/A 2023-05-24 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false Common Stock ADMP NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8ka_052423.htm admp-20230525.xsd admp-20230525_lab.xml admp-20230525_pre.xml ex23-1.htm ex99-1.htm ex99-2.htm ex99-3.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8ka_052423.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "admp-8ka_052423.htm" ] }, "labelLink": { "local": [ "admp-20230525_lab.xml" ] }, "presentationLink": { "local": [ "admp-20230525_pre.xml" ] }, "schema": { "local": [ "admp-20230525.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20230525", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8ka_052423.htm", "contextRef": "From2023-05-25to2023-05-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8ka_052423.htm", "contextRef": "From2023-05-25to2023-05-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001387131-23-007603-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-007603-xbrl.zip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�>39%3H*0]"JW<]R7J\IR^,X;TWG&) M?;G%LIO;]A_MJ^_M])3:$A:XME@3]HG)JH'0N>I\%0Y)*L9W_2GLYVBJD:HW MB1PFW]3K6AEX(5XWJDDG'=;$*6=/D"VGCJ4X6^<(T](HEPUFF 0%9?)X0[U8 M5.Q#[."I[\"1@,O$5O3SBZI>W4R',$NPE6)]UW)Z?"-^/4MJ>A+D-^G2A8TE MIV^J OE!WE]ZYC>5^S;W;"_OD]+ + MP"C25J7;Z]V&93]=8!G;\=B-(.=BYI-*H$*2_92M$\ 2JM(RHEE>N!?O8FEF M2S;G_E/]?WS @6K/LJK5#
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end